Product Description
For Treatment of Chronic Hepatitis C (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01740089)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biocad
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatitis A|Hepatitis C, Chronic|HIV Infections|Coinfection|Acquired Immunodeficiency Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BCD-016-3 | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2015-12-02 |
44% |
BCD-016-4 | P3 |
Completed |
Hepatitis A|Coinfection|Hepatitis C, Chronic|Acquired Immunodeficiency Syndrome|HIV Infections |
2015-08-26 |
|
PEG-IFNа-2 | P3 |
Completed |
Hepatitis A|Hepatitis C, Chronic |
2012-07-01 |